| 产品描述: | FTO抑制剂;FTO Inhibitors;;InformationFB23-2 FB23-2 is a potent and selective FTO inhibitor that directly binds to FTO and selectively inhibits FTO's N 6 -methyladenosine (m 6 A) demethylase activity with IC50 of 2.6 μM.TargetsFTO (Cell-free assay) 2.6 μMIn vitroFB23-2 directly binds to FTO and selectively inhibits FTO’s m6A demethylase activity. Mimicking FTO depletion, FB23-2 dramatically suppresses proliferation and promotes the differentiatiopoptosis of human acute myeloid leukemia (AML) cell line cells and primary blast AML cells in vitro.In vivoFB23-2 significantly inhibits the progression of human AML cell lines and primary cells in xeno-transplanted mice.Cell Research(from reference)Cell lines:Leukemia cells NB4, U937, MV4-11, ML-2; MONOMAC6 (ACC-124) cells; 293T cells; The mouse bone marrow cells FLT3ITD/NPM1, MA9 Concentrations:10 μM, 5 μM Incubation Time:24 h, 72 h |
| 靶点: |
IC50: 2.6 μM (FTO) |
| 体内研究: |
FB23-2 (2 mg/kg;腹腔注射;每天;持续 10 天) 显著抑制白血病进展并延长生存期。 FB23-2 表现出消除半衰期 (大鼠 6.7 h) 和 Cmax (大鼠 2421.3 ng/mL) 腹膜内注射后 (大鼠 3 mg/kg)。 |
| 参考文献: |
1. Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019 Apr 15;35(4):677-691.e10. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.549 ml |
12.747 ml |
25.495 ml |
| 5 mM |
0.51 ml |
2.549 ml |
5.099 ml |
| 10 mM |
0.255 ml |
1.275 ml |
2.549 ml |
| 50 mM |
0.051 ml |
0.255 ml |
0.51 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |